Ironwood Ends Phase III GERD Program, Will Cut 100 Jobs
IW-3718 Development Discontinued After Interim Analysis
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
